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Abstract
NELL-1 is a novel secreted protein associated with premature fusion of cranial sutures in craniosynostosis that has been
found to promote osteoblast cell differentiation and mineralization. Our previous study showed that Runx2, the key
transcription factor in osteoblast differentiation, transactivates the NELL-1 promoter. In this study, we evaluated the
regulatory involvement and mechanisms of Osterix, an essential transcription factor of osteoblasts, in NELL-1 gene
expression and function. Promoter analysis showed a cluster of potential Sp1 sites (Sp1/Osterix binding sites) within
approximately 70 bp (from 271 to 2142) of the 59 flanking region of the human NELL-1 transcriptional start site. Luciferase
activity in our NELL-1 promoter reporter systems was significantly decreased in Saos-2 cells when Osterix was overexpressed.
Mutagenesis study demonstrated that this suppression is mediated by the Sp1 sites. The binding specificity of Osterix to
these Sp1 sites was confirmed in Saos-2 cells and primary human osteoblasts by EMSA in vitro and ChIP assay in vivo. ChIP
assay also showed that Osterix downregulated NELL-1 by affecting binding of RNA polymerase II to the NELL-1 promoter,
but not by competing with Runx2 binding to the OSE2 sites. Moreover, NELL-1 mRNA levels were significantly decreased
when Osterix was overexpressed in Saos-2, U2OS, Hela and Glioma cells. Correspondingly, knockdown of Osterix increased
NELL-1 transcription and osteoblastic differentiation in both Saos-2 cells and primary human osteoblasts. These results
suggest that Osterix is a direct transcriptional regulator with repressive effect on NELL-1 gene expression, contributing to a
delicate balance of regulatory effects on NELL-1 transcription with Runx2, and may play a crucial role in osteoblast
differentiation and mineralization. These findings also extend our understanding of the molecular mechanism of Runx2,
Osterix, and NELL-1 and demonstrate their crosstalk during osteogenesis.
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Introduction
Through promoter analyses, we recently established NELL-1, a
Nel-like molecule-1 [1,2], as a novel direct transcriptional target of
runt homology domain transcription factor-2 (Runx2) [3]. Site-
directed mutagenesis and chromatin immunoprecipitation (ChIP)
assays revealed at least three functional consensus osteoblast
specific binding elements 2 (OSE2) on the human NELL-1
promoter. Significantly, the overexpression of NELL-1 was
originally found in pathologically fusing and fused sutures in
nonsyndromic unilateral coronal synostosis (UCS) patients [4],
and CMV-Nell-1 overexpression mice exhibited CS-like phenotypes
that ranged from simple to compound synostoses [5]. These
findings highly suggest that NELL-1 is a CS-associated factor with
preferential osteogenic effects on cells of the osteochondral lineage.
Furthermore, N-ethyl-N-nitrosourea (ENU)-induced Nell-1 defi-
cient mice revealed major abnormalities in the skeletal system such
as decreased calvarial bone mineralization and decreased vertebral
disc volume, and perinatal death due to respiratory failure
secondary to a deformed cartilaginous ribcage [6]. This Nell-1
deficient mouse model in addition to the overexpression transgenic
mouse model further supports the critical role of Nell-1 in the
Runx2 regulatory network of osteogenesis, however, the precise
mechanism of action of Nell-1 remains unknown [7,8].
Osterix/Sp7 (Osx), a member of the Sp1 transcription factor
family, is also essential for osteoblastogenesis [9,10,11]. Like
Runx2-null mice, Osterix-null mice exhibit complete absence of
bone matrix and osteoblasts, indicating an absolute requirement
for Osterix in osteoblast formation [9]. However, Osterix-null
mice exhibit normal cartilage hypertrophy while Runx2-null mice
do not. In addition, Osterix-null mice exhibit normal Runx2
levels, while Osterix is not expressed in Runx2 null-mice
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Runx2. The Osterix promoter does contain at least one functional
Runx2 binding site [12], however, Osterix can be induced by
BMP2 in Runx2-null cells [13], possibly through upregulation of
Dlx5 and its phosphorylation by p38. Thus, Osterix exhibits both
Runx2 dependent and independent regulation. Previous studies
have suggested that Osterix functionally segregates osteoblast and
chondrocyte lineages whereby bipotential precursor cells initially
express Runx2 and then express Osterix to suppress chondrogenic
lineage and promote osteoblast differentiation [14]. Consistent
with this, Kaback et al. demonstrated Osterix expression in
perichondrium, immature chondrocytes, and osteoblasts, but not
hypertrophic chondrocytes during development [15].
Interestingly, the transduction of AdNell-1 inhibited Osterix
mRNA expression without affecting Runx2 mRNA levels during
osteoblastic differentiation of preosteoblastic MC3T3 cells [5,16],
which may indicate a potential regulatory and functional relation-
ship between Nell-1 and Osterix in addition to what has been
discovered between Nell-1 and Runx2 in osteoblastic differenti-
ation, leading us to pursue this current study. Here we
demonstrated that overexpression of Osterix can suppress NELL-
1 expression at the transcriptional level in multiple human
osteoblast-like and non-osteoblastic cell lines, and verified that
this inhibitory effect on NELL-1 expression with and without
Runx2 induction involves Osterix direct binding of Sp1 sites in the
NELL-1 promoter in a human osteosarcoma cell line, Saos2. We
also verified that Nell-1 has inhibitory effects on Osterix expression
during osteoblastic differentiation reciprocally. Taken together, we
conclude that a delicate balance of regulatory effects on Nell-1
transcription by Osterix and Runx2 is crucial, and these novel
findings provide new insights into the underlying mechanism of
Nell-19s action during osteochondral differentiation.
Materials and Methods
Cell Culture
Saos-2 cell line was purchased from ATCC (Manassas, VA) and
primary human osteoblast cells (HOb) were purchased from Cell
Applications Inc (San Diego, CA). Cells were cultured in growth
medium of Dulbecco’s modified Eagles’ medium (DMEM) with
10% fetal bovine serum (FBS), 100 units/ml penicillin, and
100 mg/ml streptomycin or osteoblastic differentiation medium
containing additional 50 ug/ml ascorbic acid and 10 mM beta-
glycerophosphate in the growth medium. Cells were plated at a
density of 2.5610
4 cells/cm
2 in DMEM for the experiments.
Reporter and Expression Constructs
The p2213WT-Luc and p325WT-Luc vectors containing the
human NELL-1 promoter fragment were generated as described
previously [3]. Mutant constructs of the p325WT-Luc promoter
including p325mut all-Luc with mutation in all Sp1 sites of both
cluster Site A and Site B, p325mutSiteA-Luc with mutation in
cluster Site A, and p325mutSiteB with mutation in Site B were
produced by GenScript USA Inc. (Piscataway, NJ). Human Osterix
expression construct (pcDNA3.1-Osterix, pOsx), generated by
RT-PCR from Saos-2 cell cDNA, and empty pcDNA3.1 control
vector (pCtr) were utilized for all co-transfection experiments. The
Runx2 expression plasmid (pRunx2) was a generous gift from Dr.
Wenfang Wang of Harvard University. Renilla control plasmid
was purchased from Promega (Madison, WI). All constructs were
confirmed by reproducible sequencing (Laragen, Los Angeles,
CA). Each experiment was repeated at least 3 times. The data is
presented as the mean 6 SD. A t-test was performed, with p,0.05
considered statistically significant [3].
Transient Transfection and Reporter Assay
Cells in 6 well plates were transfected and grown to 80–90%
confluence with Lipofectamin 2000 (Invitrogen, Carlsbad, CA).
For each reaction, the plasmid DNA (promoter-luciferase vectors
p2213WT-Luc or p325WT-Luc plus Renilla plasmid, with pOsx
or pCtr constructs) was transfected according to the manufactur-
er’s instructions. Forty-eight hours after transfection, the cultures
were harvested, and luciferase activity was assayed using Dual-
Luciferase Assay System (Promega, Madison, WI), and then
normalized by co-transfected Renilla activity. Each experiment
was repeated at least 3 times. The data is presented as the mean 6
SD. A t-test was performed, and p,0.05 was considered
statistically significant [3]. Total RNA of transfected cells was
isolated by Trizol Reagent (Invitrogen, Carlsbad, CA), and the
expression levels of NELL-1 and other genes were detected by real-
time PCR.
Electrophoretic Mobility Shift Assays
Preparation of nuclear extracts from Saos-2 cells transfected
with pCtr or pOsx were performed using Nuclear Extract Kit
(Pierce, Rockford, IL) according to the manufacturer’s protocol.
Briefly, cells were harvested in ice-cold PBS supplemented with
phosphatase and protease inhibitors, then lysed in hypotonic
buffer and 1% Triton X-100. After collection of the cytoplasmic
fraction, nuclei were lysed and the nuclear extract proteins were
solubilized in lysis buffer supplemented with 10 mM DTT, and
protease inhibitor cocktail. According to the human NELL-1
promoter analysis (Fig. 1), we designed two oligos, Site A
containing three overlapping Sp1 sites and Site B containing a
single Sp1 site. The mutated Site A oligo (Mut
A) has a mutation in
every Sp1 site while the mutated Site B oligo (Mut
B) has the same
mutation at its Sp1 site. Oligonucleotide probes labeled with and
without biotin were generated from Invitrogen. Sequences
used include: Site A: 59-GCGGTGGGGGGCGGGCTGGG-
GGCGGGGCGGCCGGGGCTG-39, Mut
A:5 9-GCGGTGGG-
GGAAGGGCTGGGGAAGGGAAGGCCGGGGCTG-39, Site
B: 59-GCCGCAGCGGGGGGCCGGGCCCCGAGCCCC-39,
and Mut
B:5 9-GCCGCAGCGGGGGGAAGGGCCCCGAGCC-
CC-39. The EMSA protocol followed the LightShift Chemilumi-
nescent EMSA Kit (Pierce, Rockford, IL) instructions. Briefly,
2 mg of nuclear extract protein (NE) plus biotin labeled
oligonucleotide with and without anti-Osterix (Abcam, Cam-
bridge, MA) in 20 ml binding system (containing 2.5% glycerol,
5 mM MgCl2, 50 ng/ml poly (dI?dC), 0.05% NP-40 and 1x
binding buffer) was incubated at room temperature for 20 minutes.
Five ml of 5x loading buffer was added to each 20 ml binding
reaction, then 20 ml of each sample was loaded onto the 5%
polyacrylamide gel in 0.5x TBE. Samples were electrophoresed
until the bromophenol blue dye had migrated approximately 3/4
down the length of the gel. The gel and nylon membrane were
sandwiched in a clean electrophoretic transfer unit, and trans-
ferred at 380 mA (,100V) for 30 minutes. Then DNA and
membrane were crosslinked using a UV-light cross-linker
instrument. Biotin-labeled DNA was detected by Chemilumines-
cence provided by the LightShift Chemiluminescent EMSA Kit
(Pierce, Rockford, IL). The unlabeled oligos of Site A and Site B at
20x and 200x or 200x mutated Site A and Site B were added to
compete specifically with labeled oligo binding in the competitive
EMSA.
Chromatin Immunoprecipitation Assays
Saos-2 cells and primary human osteoblasts were used for
chromatin immunoprecipitation (ChIP) assays with the One-day
ChIP-qPCR kit (SABiosciences, Frederick, MD) according to the
Osx Negatively Regulated NELL-1
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formaldehyde for 10 minutes at 37uC. Cross-linked lysates were
treated with glycine to stop the fixation reaction. Lysates were
resuspended in shearing buffer and then sonicated to shear
chromatin. Cross-linked lysates were immunoprecipitated with
anti-Osterix (Abcam, Cambridge, MA), anti-Runx2 (Santa Cruz
Biotechnology, Inc, Santa Cruz, CA), or non-specific IgG
(SABiosciences, Frederick, MD) antibodies. Then DNA was
recovered and used for qPCR with NELL-1 promoter primer
pairs designed and provided by SABiosciences following the
manufacturer’s instructions. The human RNA Polymerase II
ChIP-grade antibody and human GAPDH ChIP-qPCR control
primer were provided in the ChampionChIP kit. The NELL-1 -
1 kb primer set (NM_006157.2 201 kb) covers 1 kb proximal
promoter region where all Sp1/Osterix binding sites and three
OSE2 sites are located, and the NELL-1 22 kb primer set
(NM_006157.2 202 kb) covers the NELL-1 promoter region from
21k bt o22 kb where no Sp1 site and one OSE2 site exists
(Fig. 1). Each experiment was repeated at least 3 times. The data
is presented as the mean 6 SD. A t-test was performed, with
p,0.05 considered statistically significant [3].
Reverse Transcription-PCR and Real-Time PCR
One mg of DNase I treated total RNA were used for reverse
transcription. The ABI Prism 7300 Real Time PCR System was
utilized to quantify gene expression in the exponential phase of
PCR reactions. TaqMan primer-probe sets for osteocalcin (Ocn),
osteopontin (Opn), NELL-1, Osterix, and glyceraldehyde-3-phosphate
dehydrogenase (Gapdh) were purchased (Applied Biosystems, Foster
City, CA) and analyzed by real time PCR as previously described
[5]. Relative gene expression profiles were calculated using the
comparative quantification formula as 2
2DDCt based on the
evaluation of similar dynamic ranges for RT-PCR efficiency of
both Gapdh and the target genes. Each experiment was repeated at
least 3 times. The data is presented as the mean 6 SD. A t-test was
performed, with p,0.05 considered statistically significant [3].
Transfection of Osterix siRNA into Saos-2 cells and
primary human osteoblasts
Human Osterix siRNA oligos were designed and synthesized by
Invitrogen (Silencer Select pre-designed siRNA s42458, s42459
and s42460 against Osterix mRNA). Saos-2 cells or human
osteoblasts were seeded at 2.5610
4/cm
2 into 6 well plates and
allowed to reach 50% confluence the following day for siRNA
transfection. Thirty pg/well of control siRNA or Osterix siRNA
oligos mixture per well was added with the Lipofectamin 2000
reagent (Invitrogen, Carlsbad, CA) following the manufacturer’s
instructions. The blocking efficacy for the expression of human
Osterix mRNA was measured at 2 days and 7 days post-transfection
with real time PCR. Each experiment was repeated at least 3
times. The data is presented as the mean 6 SD. A t-test was
performed, with p,0.05 considered statistically significant [3].
Results
NELL-1 promoter contains multiple putative Sp1 sites
(Sp1/Osterix binding sites)
In silico analysis of the human NELL-1 promoter identified a
cluster of potential Sp1 sites (Sp1/Osterix binding sites) within
approximately 70 bp of the 59 flanking region of the human NELL-
1 gene (from 271 to 2142 bp upstream of the NELL-1
transcriptional start site) (www.gen matix.de). Within this cluster,
Site A contains three overlapping potential Sp1 sites from 271 to
296 and Site B contains a single Sp1 site from 2133 to 2142
(Fig. 1). In comparison to the human NELL-1 promoter, the
mouse Nell-1 promoter also contains multiple putative Sp1 sites
that reside at 2107, 2149, 2195, 2524, 2536 and 2971 bp
upstream of the transcriptional start site. Similarly, a cluster of Sp1
sites was also identified by virtue of their proximity and
overlapping consensus sequences between the fourth and fifth
Sp1 sites (Fig. 1). To better illustrate the spatial distribution of Sp1
sites in both human and mouse Nell-1 promoters, the locations of
previously identified Runx2 binding sites OSE2 are also displayed
in Fig. 1, with three functional sites labeled A, B, C and a cryptic
site H1 in the human NELL-1 promoter, and two sites labeled site
1 and 2 and a cryptic site m1 in the mouse promoter region. The
presence of multiple Sp1 binding sites in the NELL-1 promoter
across species of mouse and human is a good indication that
NELL-1 transcription may also be directly regulated by Osterix in
addition to Runx2.
Human NELL-1 promoter is responsive to Osterix by
reporter assay
To investigate whether the Sp1 sites contribute to NELL-1
transcription, we used the human NELL-1 promoter reporter
systems 22213bp (p2213WT-Luc) and 2325bp (p325WT-Luc) as
Figure 1. Schematic of the human and mouse Nell-1 promoters (not drawn to scale). In silico analysis identified a cluster of potential Sp1/
Osterix binding sites within approximately 70 bp of the 59 flanking region of the human NELL-1 gene. Within the cluster, Site A contains three
overlapping potential Sp1 sites from 271 to 296 bp and Site B contains a single Sp1 site from 2133 to 2142 bp. Four OSE2 sites to which Runx2
binds in human NELL-1 promoter are also shown (labeled A, B, C and H1). A similar pattern is seen in mouse Nell-1 promoter. Multiple putative Sp1
sites (labeled Site a,e) are located before three OSE2 sites (labeled 1, m1 and 2). The relative location of primers for CHIP assay are indicated on the
human 2.2 kb promoter.
doi:10.1371/journal.pone.0024638.g001
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opublished [3]. These systems contain a 2213 bp or 325 bp length
of genomic DNA upstream of the human NELL-1 transcription
start site. We confirmed the presence of these putative Sp1 sites at
predicated positions by full-length sequencing (Laragen, LA, CA)
(Fig. 1). Co-transfection experiments were performed to examine
a dose–dependent response for both promoter constructs in Saos-2
cells. The Saos-2 cell line was chosen as a suitable system to study
the human promoter and was previously used to study human
NELL-1 promoter OSE2 sites [3]. Saos-2 cells have endogenous
expression of both Osterix [17] and NELL-1, and have the
necessary osteoblast-related factors for differentiation and forma-
tion of mineralized bone nodules [18,19]. Saos-2 cells transfected
with the p2213WT-Luc and 0.25 mgt o1mg Osterix expression
vector (pOsx) had up to 80% decrease in luciferase activity in a
dose-dependent manner compared to Saos-2 cells transfected with
the p2213WT-Luc and control vector (pCtr) 2 days after
transfection. Although the basal luciferase activity is reduced in
the truncated p325WT-Luc construct group since it lacks 3
consensus OSE2 sites [3], the truncated construct with pOsx
showed a similar percent decrease compared to control vector
(Fig. 2A), indicating that the short fragment containing these Sp1
sites in the p325WT-Luc construct are responsible for Osterix to
down-regulation of luciferase activity.
Osterix forced expression decreases NELL-1 mRNA levels
in human osteoblast-like and non-osteoblastic cells
To investigate whether Osterix controls endogenous NELL-1
gene expression, Saos-2 cells were transiently transfected with
either an empty vector or different amounts of Osterix expression
constructs for 2 days and 7 days. Saos-2 cells were chosen for this
analysis because we have previously shown that the high
expression level of NELL-1 in these cells can induce several
osteoblastic maker genes such as Opn and Ocn and promote their
differentiation and mineralization [3]. The Osterix protein levels
in Saos-2 cells transfected with different amounts of pOsx were
detected by Western blot (Fig. 2B). In this study, the forced
expression of Osterix in Saos-2 cells significantly decreased NELL-1
expression at 2 days post-transfection in a dose–dependent
manner, and continued to reduce the levels for up to 7 days
(Fig. 2B).
In addition to the Saos2 cells, the transcriptional repression of
Nell-1 promoter by Osterix was also detected in other human cell
lines including an immature osteoblast, U2OS cells and two non-
osteoblastic cell lines, Hela and Glioma cells (Fig. 2C). Similar
results in these cell lines compared to results in Saos2 cells further
suggest that the transcriptional repression of NELL-1 promoter by
Osterix exists in human cells irrespective of tissue origin or degree
of osteoblastic maturity.
Sequence specific binding of Osterix to Sp1 sites within
the NELL-1 promoter
Since all these Sp1 sites lie within the 325bp promoter of the
proximal NELL-1 transcriptional start site, to determine the
functional relevance of all Sp1 sites in Osterix-mediated decrease
of NELL-1 promoter activity, we generated a mutant promoter
construct (p325mut all-Luc, Genscript Co, Piscataway, NJ)
containing an alteration of the Sp1 sites by point mutation known
to disrupt Osterix binding [9] (Fig. 3A). This mutant construct,
p325mut all-Luc with mutations in all Sp1 sites of both cluster Site
A and Site B, was transfected into Saos-2 cells and the downstream
reporter gene luciferase activity was analyzed with and without
forced Osterix expression. The Osterix-induced suppression of
luciferase activity was statistically significant in the wild type
construct p325WT-Luc (p,0.05) (Fig 3B). Furthermore, the
complete suppression of Osx inhibitory effect was observed in
the p325mut all-Luc construct as compared to p325WT-Luc in
the setting of Osterix overexpression (p,0.05). This result strongly
indicates that these Sp1 sites of the Nell-1 promoter are required
for Osx binding in regulating NELL-1’s transcription.
To determine which Sp1 site is more important to induce the
suppression, we made two additional mutant reporter constructs,
p325mutSiteA-Luc with mutations in cluster Site A, and
Figure 2. Dose-dependent NELL-1 expression response to
Osterix. (A) Human NELL-1 promoter is responsive to Osterix in a
dose-dependent manner shown by reporter assay. Graph detailing
the luciferase activity in Saos-2 cells co-transfected with either the
p2213WT-Luc or the p325WT-Luc promoter-luciferase constructs as well
as 0, 0.25, 0.5, or 1 ug of Osterix expression vector (pOsx). Data are
expressed as a percentage of the luciferase activity of the p325WT-Luc
construct in the absence of control vector (pCtr). (B)O s t e r i x
overexpression decreased NELL-1 mRNA level in Saos-2 cells at 2 days
and 7 days post-transfection. Western blot showed Osterix protein
levels at 2 days and 7 days post-transfection. (*p,0.05) (C) Osterix
transcriptional repression of NELL-1 promoter in osteoblastic and non-
osteoblastic cells. A graph detailing the luciferase activity of p325WT-
Luc 2 days post-transfection in Saos-2, U2OS, Hela and Glioma cell lines
co-transfected with pCtr or pOsx. (*p,0.05)
doi:10.1371/journal.pone.0024638.g002
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luciferase activity by expression of Osterix was still observed when
either p325mutSiteA or p325mutSiteB constructs were used.
However, the levels of Osterix overexpression-mediated suppres-
sion in these constructs were significantly diminished in compar-
ison to p325WT construct (p,0.05) (Fig. 3B). These results
indicate that both Site A and Site B have functional roles in the
suppression of NELL-1 when bound by Osterix, and both are
absolutely necessary and responsible for the complete suppression
of Osx inhibitory effect on NELL-1’s transcription when they are
mutated simultaneously (p,0.05).
To further examine DNA-protein interactions at these Sp1 sites,
EMSAs using Saos-2 nuclear extracts and the respective
oligonucleotide probes containing the Sp1 sites were performed.
Since these Sp1 sites were within 70 bp in the NELL-1 proximal
promoter, we divided them into two respective oligonucleotide
probes in our experiment—Site A (from 2101 to 262 bp
upstream of NELL-1) containing three overlapping potential Sp1
sites and Site B (from 2153 to 2124 bp upstream of NELL-1
transcriptional start site) containing a single Sp1 site.
Since Tomohiro reported that Sp1/Sp3 can also occupy the
Sp1 sites in Saos-2 cells [17], we force expressed Osterix in Saos-2
cells to increase its amount in the nuclear extract (NE) for gel shift
assay. We were then able to find the main protein-DNA (Osterix-
Site A and Osterix-Site B) complex bands in the two groups with
and without Osterix overexpression (Fig. 4A). These protein-
DNA complex bands were confirmed by super shift assay when
Osterix antibody was added (Fig. 4A).
Furthermore, specificity of binding to the Sp1 site was
confirmed by competition analysis with WT probes and by
mutant probes containing 2 bp mutations known to disrupt
Osterix binding described in mutant reporter systems. Incubation
of NE from Saos-2 cells transfected with pOsx led to the formation
of protein–DNA complexes with WT oligonucleotides. In contrast,
the oligonucleotides harboring the 2 bp mutations had no protein-
DNA complexes detected (Fig. 4B). Binding of the promoter sites
by labeled WT probe was diminished with the addition of 20x and
200x unlabeled WT oligonucleotide, but no effect was seen with
the addition of 200x unlabeled mutated oligonucleotides (Fig. 4B).
These results demonstrate that Osterix is indeed part of the DNA-
protein complex in the NELL-1 promoter and indicate that NE
from Saos-2 cells has Osterix that can specifically bind to the Sp1
sites of the human NELL-1 promoter.
Osterix binding to the endogenous NELL-1 promoter
in vivo
Since our reporter assay and EMSA studies described above
indicate that Osterix protein recognized these Sp1 sites in the
human NELL-1 promoter, we next examined whether Osterix is
able to interact directly with the NELL-1 promoter in vivo. To study
this we used ChIP-qPCR assay (ChampionChIP One-Day kit,
SABiosciences, Frederick, MD) to examine the binding of
Osterix to the NELL-1 promoter region in Saos-2 cells. The
qPCR products between anti-Osterix and control IgG showed a
significant difference in the NELL-1 promoter 21 kb group, but
the difference was not seen in the NELL-1 promoter 22 kb group
(Fig. 4C), suggesting that Osterix can directly interact with NELL-
1 promoter in vivo and specifically bind to the chromatin fragment
containing these Sp1 sites region covered by specific NELL-1
promoter 21 kb qPCR primer. To further confirm this finding we
also performed the ChIP-qPCR assay in primary human
osteoblast cells. The results indicated the existence of similar
recessive regulatory relationship of Osterix and Nell-1 through
direct binding of Osterix to Sp1 sites of Nell-1 promoter (Fig. 4D).
These results further verify that endogenous Osterix both in Saos-
2 cells and primary human osteoblast specifically associate with
these Sp1 sites in the endogenous human NELL-1 promoter, and
that Osterix is directly involved in the regulation of NELL-1 gene
activity through its physical interaction with the NELL-1 promoter.
Osterix down regulates NELL-1 expression without
disruption of Runx2 binding to NELL-1 promoter OSE2
sites
Because our previous study showed that Runx2 positively
regulates NELL-1 expression through three consensus and one
cryptic OSE2 site (H1) in the NELL-1 promoter, here we co-
transfected Osterix and Runx2 with p2213-Luc or p325-Luc
constructs to detect Osterix effects on Runx2 induced NELL-1
promoter activity. The reporter systems were co-transfected with
pRunx2 and reporter constructs plus pOsx or pCtr. The luciferase
activity after treatment with pOsx was significantly reduced
compared to treatment with pCtr in both p2213WT-Luc and
p325WT-Luc groups (Fig. 5A). This result suggests that high level
Osterix can suppress Runx2 induced NELL-1 expression. In order
to determine whether this suppression is mediated through these
Sp1 sites, we used the construct (p325mut all-Luc) with all mutated
Figure 3. Both Site A and Site B are functional for Osterix-
mediated NELL-1 promoter activity suppression. (A) Schematic
of p325WT-Luc, p325mut all-Luc, p325mutSiteA, and p325mutSiteB
constructs. Blue represents mutated Sp1 sites. (B) Graph depicting
promoter activity on Saos-2 cells cotransfected with pOsx as well
as p325WT-Luc or mutated NELL-1 promoter-luciferase constructs
(p325mut all-Luc, p325mutSiteA-Luc, and p325mutSiteB-Luc, respec-
tively). Data are reported as percent activity of control cells transfected
with pCtr. (*p,0.05)
doi:10.1371/journal.pone.0024638.g003
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p325mut all-Luc group, there was no difference in luciferase
activity between pOsx and pCtr (Fig. 5A) indicating that the
suppression of Runx2 induced NELL-1 expression by Osterix
requires functional Sp1 sites.
Our previous NELL-1 promoter analysis also showed that these
Sp1 sites (271,2142 bp) are located proximal to the Runx2
OSE2 binding site (H1, 2247 bp). It is possible that Osterix down
regulation of NELL-1 promoter activity is mediated by suppression
of Runx2 binding to the H1 site. Therefore, ChIP-qPCR assay
Figure 5. Osterix down regulates Runx2-induced NELL-1 promoter activity. (A) Graph depicting promoter activity in Saos-2 cells after co-
transfection with control empty pcDNA3.1 vector (pCtr), pcDNA-Runx2 (pRunx2) or pRunx2 plus pOsx expression vectors as well as p2213-Luc, p325-
Luc or p325mut-Luc NELL-1 promoter-luciferase constructs. Data are reported as fold changes in comparison to control cells transfected with pCtr
and p325WT-Luc constructs. (p,0.05) (B) Osterix affects binding of RNA polymerase II to NELL-1’s promoter, but does not compete with Runx2
binding of OSE2 sites. The NELL-1 -1 kb primer set used covers 1 kb proximal promoter region where all Sp1/Osterix binding sites and three OSE2
sites are located. The qPCR products depict DNA amplified from Chromatin Immunoprecipitation with Saos-2 cells transfected with pCtr or pOsx
utilizing Control IgG, Osterix antibody, Runx2 antibody or RNA polymerase II antibody. Input DNA represents positive genomic DNA control.
(*p,0.05)
doi:10.1371/journal.pone.0024638.g005
Figure 4. Osterix specifically binds to Sp1 sites in the NELL-1 promoter in vitro and in vivo. (A) EMSA of Saos-2 nuclear proteins transfected
with pCtr or pOsx binding to SiteA (containing three proximal Sp1 sites) and SiteB probes. Supershifts with specific Osterix antibody indicate the
specific Osterix-DNA complexes. (B) EMSA depicting primary human osteoblast cell (hOB) nuclear proteins transfected with pOsx binding to the SiteA
probes, with competition by 20x and 200x unlabeled SiteA and 200x unlabeled mutated SiteA (MutA) oligonucleotides. Note that the MutA probes
failed to bind nuclear proteins. The same pattern is also seen by competition of SiteB element and MutB.( C–D) Osterix binds to endogenous Sp1 sites
of the human NELL-1 promoter in Saos-2 (C) and hOB (D) cells. The NELL-1 -1 kb primer set covers 1 kb proximal promoter region containing all Sp1/
Osterix binding sites and three OSE2 sites. The NELL-1 -2 kb primer set covers NELL-1 promoter region from 21k bt o22 kb where no Sp1/Osterix
binding site but one OSE2 site exists. The qPCR products depict DNA amplified from Chromatin Immunoprecipitation with cells utilizing Control IgG
and Osterix antibody. Input DNA represents positive genomic DNA control.
doi:10.1371/journal.pone.0024638.g004
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with and without Osterix forced expression. The same amount of
chromatin was used for ChIP assay plus control IgG, Osterix
antibody, Runx2 antibody and general transcriptional factor RNA
polymerase II antibody. ChIP-qPCR products were normalized by
endogenous GAPDH amounts between Osterix transfection and
control vector groups. The results showed that Osterix binding to
NELL-1 promoter was significantly increased in the Osterix forced
expression group compared to control vector group. There was no
obvious difference seen in Runx2 binding to NELL-1 promoter
with and without Osterix forced expression (Fig. 5B). Interest-
ingly, the general transcription factor RNA polymerase II binding
to NELL-1 promoter was significantly decreased in the Osterix
overexpression group (Fig. 5B), indicating one possible mecha-
nism for Osterix negative regulation of NELL-1 promoter activity.
Osterix siRNA increases NELL-1 mRNA levels in Saos-2
cells concomitantly with increased mineralization
The data showed that Osterix forced expression decreases
NELL-1 mRNA levels in Saos-2 cells (Fig. 2B). To further
demonstrate the effect of suppression, we also analyzed other
osteoblastic marker mRNA levels after Osterix overexpression in
Saos-2 cells and primary human osteoblasts. Interestingly, some
markers such as Ocn and Opn expression levels also decreased
following the decrease of NELL-1 expression at 2 days post-
transfection (Fig. 6A). However, by 7 days post-transfection, Ocn
and Opn expression levels showed no significant difference between
the pCtr and pOsx groups in Saos-2 cells. Moreover, Ocn
expression level also decreased in a similar fashion as Nell-1 at 2
days post-transfection in primary human osteoblasts (Fig. 6B), but
Opn expression patterns were different between Saos-2 osteosar-
coma cells and normal primary human osteoblast cells, which may
indicate that overexpression of Osterix plays a transient and more
complicated role with variable effects on bone marker gene levels
at different stages of maturation of human osteoblasts.
To further confirm Osterix suppression of NELL-1 expression,
we inhibited Osterix mRNA level using siRNA in Saos-2 cells and
primary human osteoblasts. Data showed that NELL-1 mRNA
levels increased almost 3 fold 2 days after Osterix siRNA
transfection at which time Osterix mRNA expression levels were
decreased by 80% in Saos-2 cells (Fig. 6A). Ocn and Opn
expression also increased slightly 2 days after transfection. At post-
transfection day 7, when Osterix mRNA levels were still less than
30%, NELL-1 mRNA levels continued to be elevated. NELL-1 and
Ocn mRNA levels also increased in a similar pattern at 7 days post-
transfection (Fig. 6A). To further confirm Osterix regulation of
NELL-1 in mature osteoblast cells, these experiments were
performed in human primary osteoblasts. Although the inhibition
efficiency of Osx-siRNAs (around 50%) in this cell line is less than
that in Saos-2 cells at Day 2, NELL-1 mRNA levels showed
significant increase along with significant changes in other bone
markers (Ocn and Opn) after 7 days post Osterix siRNA transfection
(Fig. 6B). Alizarin Red staining was also used to detect minera-
lization during osteoblast differentiation. Osterix siRNA transfec-
tion increased the mineralization of Saos-2 cells at 9 days post-
transfection (data not shown), consistent with bone marker gene
mRNA level increase in Osterix siRNA assay.
Discussion
NELL-1 is a novel osteoinductive factor under direct transcrip-
tional regulation of Runx2 [3,5], the master transcription factor of
osteogenesis [20]. Osterix is another essential transcription factor
for osteoblast differentiation and bone formation directly down-
stream of Runx2 [12]. In this study we sought to determine the
regulatory and functional relationship between these two down-
stream targets of Runx2, in particular to validate the functional
characteristics of potential Osterix binding sites in the human
NELL-1 promoter revealed by in silico analysis. Our data showed
that Osterix exhibits repressive instead of assumed inductive effect
on NELL-1 expression at the transcriptional level by binding
directly to Sp1 sites in the NELL-1 promoter region; a surprising
finding given the fact that NELL-1 and Osterix are both
considered pro-osteogenic factors [5,9,10,16,21]. This adds
NELL-1 as a member of Osterix regulated molecules that include
Col 1a [9], Col 11a2 [17], DKK1 [22] and IL-1a [23]. Like IL1-a,
NELL-1 is also negatively regulated by Osterix. In addition, we
also found that the Sp1 binding elements in the human NELL-1
promoter, identified as two clusters, Site A and B, have similar
capacity to be fully occupied by Osterix to mediate repression.
The release of this repression can occur only when Site A and B
are mutated simultaneously.
The definitive mechanisms underlying the activating or
inhibitory effects of Osterix on target promoters of these molecules
remain unclear. Interestingly, basic transcription element B1
(BTEB1), a Sp1-like protein, has been found to activate
transcription on promoters containing multiple GC boxes but
act as a repressor on promoters containing only a single GC box
[24]. This differential effect on multiple versus single GC box in
gene promoters also applies to Osterix direct targets including
activation of Col 11a2 and DKK1 which both have multiple
binding sites, and repression of IL-1a which has a single binding
site. However, this rule does not apply to all targets of Osterix, as
Col 1a which has a single binding site is activated, not repressed,
by Osterix, while Nell-1 with multiple sites is repressed. Col 1a
regulation is more complex, as its regulation has been reported to
also involve NFATc1 as a co-factor that forms a complex with
Osterix to bind the consensus Sp1 binding site [10]. It is possible
that NFATc1 may modulate Osterix-mediated transactivation by
recruitment of other transcriptional co-activators [10]. Most
recently, another co-factor of Osterix, NO66, a Jumonji family
histone demethylase, has been reported to impair transcriptional
activation of Osterix through interaction with the Osterix
activation domain. In particular, the interaction between Osterix
and NO66 is believed to regulate Osterix target genes in
osteoblasts through modulating histone methylation [25]. Osterix
transcriptional repression of Nell-1, a gene expressed preferentially
in osteoblasts, may therefore also involve a co-factor leading to the
negative effect on NELL-1 promoter activity.
Runx2 is known as the master regulator of osteochondrogenesis,
promoting commitment, clonal expansion, and early osteoblastic
differentiation [26,27], and is a direct upstream regulator of NELL-
1 gene expression [3]. Our previous studies have demonstrated
that Runx2 directly activates NELL-1 transcription by physically
binding to OSE2 sites on its promoter region [3]. In this current
study, reporter system assays confirmed that Osterix directly
represses Runx2-induced NELL-1 expression through binding of
multiple Sp1 sites on its promoter. Mechanistically, by using
CHIP-qPCR assay, we were able to demonstrate that there was no
difference in Runx2 binding of NELL-1 promoter OSE2 sites with
and without Osterix forced expression. This demonstrates that
Osterix-mediated down-regulation of NELL-1 expression does not
involve disruption of Runx2 binding of the NELL-1 promoter
OSE2 sites. Instead, we found that general transcription factor
RNA polymerase II binding to the NELL-1 promoter is
significantly decreased when Osterix is overexpressed, which
may interfere with initiation of NELL-1 gene transcription [28].
However, the exact role Osterix plays, along with RNA
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without Runx2 induction remains unclear and warrants further
study. Notably, there has been no evidence to date that Osterix
and Runx2 interact with each other directly to alter their DNA
binding and promoter transactivating activities [26].
To determine how Osterix repressive transcriptional regulation
of NELL-1 affects its osteogenic activity, we performed in vitro
osteoblastic differentiation studies with either overexpression or
specific siRNA knockdown of Osterix in Saos2 as well as in normal
primary human osteoblast cells. Expectedly, the mRNA expression
of NELL-1 was severely inhibited by overexpression of Osterix.
Notably, NELL-1 repression was associated with the early transient
decrease of Ocn and Opn mRNA indicating some level of
impairment of NELL-1 osteoinductive capacity. In line with these
findings, over two fold upregulation of NELL-1 mRNA along with
increase of Opn at the early phase, and increase of Ocn and
mineralization at the late stage of osteoblastic differentiation were
observed after Osterix knock down by specific siRNA. Interest-
ingly, the different pattern of Opn expression between Saos-2
osteosarcoma cells and normal primary human osteoblast cells
suggests a more complicated role for Osterix in osteoblastic
differentiation at different maturation stages of human osteoblasts.
Taken together, these data definitively demonstrate the functional
impact and significance of Osterix repression of NELL-1.
Furthermore, the forced expression of NELL-1 remarkably
reduced Osterix mRNA levels in Saos-2 cells (data not shown),
demonstrating reciprocal repression of Osterix by NELL-1. This
further confirmed our previous study on MC3T3 cells that showed
transduction of AdNELL-1 inhibited Osterix mRNA expression
without affecting Runx2 mRNA levels [5,16].
The repressive regulation of NELL-1 by Osterix may seem
paradoxical given that both are known to be pro-osteoblastic, with
many reports having shown that Osterix and NELL-1 can
positively regulate osteoblast differentiation [5–7,9–11]. However,
in reality, this is not uncommon. For instance, Osterix, a pro-
osteogenic regulator, negatively regulates the Wnt signaling
pathway which is known to play a crucial role in the control of
bone mass [22]. Osterix inhibits the Wnt signaling pathway
through several mechanisms, including binding to and activating
the Wnt antagonist DKK1 promoter, or interrupting TCF binding
to its DNA elements and then suppressing downstream b-catenin
activity [22].
Studies on the inter-relationship among various factors involved
in the transcriptional regulatory network of osteogenesis are few in
number and provide only limited answers likely owing to the high
complexity of this area of study. What is known is that NELL-1 is a
critical component in regulating osteoblastic differentiation, and
that both Runx2 and Osterix are involved in its transcriptional
regulation and osteogenic function. Runx2, a positive regulator of
NELL-1, is highly expressed during transition from mesenchymal
cells to preosteoblasts and immature osteoblasts [26]. NELL-1
may be an effector of a large portion of Runx29s role, as it is a key
downstream functional mediator in this process [7]. Osterix
negative regulation of NELL-1, which is also tightly regulated by
Runx2, may result from a delicate balancing of various driving
forces in this regulatory network, modulating NELL-1 expression
levels as needed at different developmental time points. Moreover,
the overexpression of NELL-1 also affects Runx2 expression levels
or bioactivity reciprocally, adding to the complexity of the
regulatory network (Fig. 6C).
We expect that the regulatory relationship between NELL-1
and Osterix presented here from our in vitro studies is likely also
true in vivo. Our preliminary studies revealed a higher level of
Osterix expression with less mineralization in neonatal calvarial
bones in ENU-induced Nell-1 deficient mice compared to that of
wild type mice suggesting existence of a similar regulatory
relationship between Nell-1 and Osterix in vivo (data not shown).
More extensive investigation of mouse skeletal development is
needed for conclusive results, and is an area of future study for us.
Collectively, our findings through investigation of Osterix
transcriptional regulation of and functional impact on NELL-1
represent further understanding of the complex regulatory
network that governs osteochondrogenesis.
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